Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Protagonist Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Protagonist Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:17 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091123
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| License and collaboration revenue | $213,475 | $5,546 | $269,843 | $33,867 |
| Operating expenses: | ||||
| Research and development | 42,061 | 37,036 | 88,800 | 72,929 |
| General and administrative | 12,648 | 10,551 | 25,925 | 22,289 |
| Total operating expenses | 54,709 | 47,587 | 114,725 | 95,218 |
| Income (loss) from operations | 158,766 | (42,041) | 155,118 | (61,351) |
| Interest income | 6,429 | 7,406 | 12,305 | 14,979 |
| Other (expense) income, net | (81) | 36 | (28) | 118 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Protagonist Therapeutics's R&D?
- Protagonist Therapeutics (PTGX) reported R&D of $42.06M in Q2 2026.
- How has Protagonist Therapeutics's R&D changed year-over-year?
- Protagonist Therapeutics's R&D increased by 13.6% year-over-year, from $37.04M to $42.06M.
- What is the long-term trend for Protagonist Therapeutics's R&D?
- Over 4 years (2021 to 2025), Protagonist Therapeutics's R&D has grown at a 6.0% compound annual growth rate (CAGR), from $126.01M to $159.29M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Protagonist Therapeutics's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude